Nanexa AB (SE:NANEXA)
:NANEXA
Want to see SE:NANEXA full AI Analyst Report?
Top Page
Nanexa AB
(NANEXA)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr4.00
▲(32.01% Upside)
Action:Reiterated
Date:06/19/26
The score is held back primarily by continued unprofitability and substantial negative free cash flow, despite some improvement in losses. This is partly offset by a conservatively financed balance sheet with minimal debt, while technical indicators are modestly supportive and valuation remains pressured due to negative earnings and no dividend data.
Positive Factors
Partnership/licensing business model
An asset-light, partnership- and licensing-driven model creates multiple durable revenue vectors (upfronts, service fees, milestones, royalties). This diversifies cash sources across partners and program stages, reducing need for full commercial infrastructure and supporting scalable growth if deals materialize.
Negative Factors
High negative free cash flow
Deep, worsening negative free cash flow is a structural funding constraint: sustained cash burn requires external capital, which can dilute shareholders or constrain R&D cadence. Even modest operating cash improvement to date is insufficient versus large outflows, elevating financing risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership/licensing business model
An asset-light, partnership- and licensing-driven model creates multiple durable revenue vectors (upfronts, service fees, milestones, royalties). This diversifies cash sources across partners and program stages, reducing need for full commercial infrastructure and supporting scalable growth if deals materialize.
Read all positive factors
Nanexa AB (NANEXA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr643.53M
Dividend YieldN/A
Average Volume (3M)266.98K
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue Growth79.13%
EPS Growth55.77%
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.10
Shares Outstanding164,585,050
10 Day Avg. Volume346,691
30 Day Avg. Volume266,979
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)6.83
Price to Sales (P/S)19.19
P/FCF Ratio-26.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr112.20M
Nanexa AB Business Overview & Revenue Model
Company Description
Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for d...
How the Company Makes Money
Nanexa’s business model is primarily partnership- and licensing-driven around its PharmaShell drug delivery platform. The company seeks to generate revenue by collaborating with pharmaceutical and biotech companies to develop long-acting formulati...
Nanexa AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.90M | 36.15M | 24.36M | 29.33M | 2.86M | 2.37M |
| Gross Profit | 17.11M | -8.85M | 46.69M | 59.16M | 3.40M | 4.31M |
| EBITDA | -490.00K | -2.92M | -18.99M | -70.79M | -53.86M | -32.92M |
| Net Income | -16.42M | -11.39M | -24.91M | -76.40M | -58.57M | -36.00M |
Balance Sheet | ||||||
| Total Assets | 166.70M | 138.14M | 91.82M | 132.26M | 170.19M | 165.00M |
| Cash, Cash Equivalents and Short-Term Investments | 73.02M | 44.57M | 10.29M | 65.17M | 81.18M | 105.66M |
| Total Debt | 987.00K | 2.20M | 3.71M | 4.03M | 6.27M | 3.83M |
| Total Liabilities | 39.57M | 36.61M | 20.90M | 36.43M | 61.10M | 13.70M |
| Stockholders Equity | 127.13M | 101.53M | 70.92M | 95.83M | 109.10M | 151.29M |
Cash Flow | ||||||
| Free Cash Flow | -18.43M | -26.21M | -54.55M | -76.91M | -43.29M | -50.92M |
| Operating Cash Flow | 229.00K | -1.46M | -26.43M | -42.66M | -7.87M | -25.13M |
| Investing Cash Flow | -24.27M | -24.75M | -28.12M | -34.25M | -35.42M | -25.79M |
| Financing Cash Flow | 47.85M | 60.49M | -327.00K | 60.89M | 18.81M | 143.89M |
Nanexa AB Technical Analysis
Neutral
3.03
Price Trends
3.91
Positive
3.84
Positive
3.13
Positive
Market Momentum
0.12
Positive
41.59
Neutral
57.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NANEXA, the sentiment is Neutral. The current price of 3.03 is below the 20-day moving average (MA) of 4.22, below the 50-day MA of 3.91, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 41.59 is Neutral, neither overbought nor oversold. The STOCH value of 57.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NANEXA.
Nanexa AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr519.87M | -7.32 | -90.66% | ― | ― | -32.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr643.53M | -40.98 | -48.65% | ― | 79.13% | 55.77% | |
49 Neutral | kr611.69M | -12.92 | ― | ― | 9.56% | 19.12% | |
47 Neutral | kr99.09M | -225.23 | -24.83% | ― | ― | 21.82% | |
43 Neutral | kr195.06M | -4.24 | -530.21% | ― | -99.01% | -1.33% | |
43 Neutral | kr24.99M | -0.38 | ― | ― | -86.56% | 8.75% |
* Healthcare Sector Average
SE:NANEXA
Nanexa AB
3.91
1.66
73.39%
SE:ALZCUR
AlzeCure Pharma AB
3.77
1.27
51.04%
SE:VIVE
Vivesto AB
8.95
-10.98
-55.10%
SE:KLAR
Klaria Pharma Holding AB
0.79
0.37
86.15%
SE:ENZY
Enzymatica AB
2.52
-0.33
-11.58%
SE:ERMA
Enorama Pharma AB
0.34
-2.15
-86.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.